Glaukos Corporation (NYSE:GKOS) headquartered in San Clemente, will host a conference call for the investment community to discuss the 3Q20 earnings result on 5th November 2020 at 4:30 PM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.glaukos.com
Earnings Expectation
Glaukos Corporation is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, GKOS is expected to report 3Q20 loss of $ 0.48 per share from revenue of $ 53.75 million.
For the full year, analysts anticipate top line of $ 208.39 million, while looking forward to loss of $ 1.84 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 290.00 million ~ $ 300.00 million
Click Here For More Historical Outlooks Of Glaukos Corporation
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery. The companys product pipeline includes iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma; iStent Supra suprachoroidal micro-bypass stent that is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; iStent SA trabecular micro-bypass system, a two-stent product, which uses a different auto-injection inserter designed for use in a standalone procedure; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration.
